Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSONASDAQ:DRTSNYSE:ELMDNASDAQ:NYXH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$1.07-1.8%$0.96$0.70▼$1.61$66.99M1.05147,820 shs23,276 shsDRTSAlpha Tau Medical$3.07$2.79$1.75▼$4.39$216.07M0.9950,290 shs16,959 shsELMDElectromed$20.01-0.2%$21.72$13.74▼$35.56$167.80M0.472,988 shs39,298 shsNYXHNyxoah$7.56-2.5%$6.72$5.55▼$11.87$257.49M1.6575,541 shs18,467 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents-1.83%+1.90%+22.99%-2.73%+24.40%DRTSAlpha Tau Medical0.00%+5.32%+11.23%+15.85%+32.33%ELMDElectromed-0.20%-3.71%-12.35%-18.72%+35.48%NYXHNyxoah-2.45%-1.95%+30.80%-28.07%-7.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTSOCytosorbents1.9621 of 5 stars3.52.00.00.02.70.00.6DRTSAlpha Tau Medical2.9578 of 5 stars3.55.00.00.02.71.70.0ELMDElectromed1.9895 of 5 stars2.05.00.00.02.61.70.6NYXHNyxoah2.3314 of 5 stars3.53.00.00.02.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 3.00Buy$5.50414.02% UpsideDRTSAlpha Tau Medical 3.00Buy$8.00160.59% UpsideELMDElectromed 4.00Strong Buy$38.0089.91% UpsideNYXHNyxoah 3.00Buy$14.5091.80% UpsideCurrent Analyst Ratings BreakdownLatest CTSO, NYXH, DRTS, and ELMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/15/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.005/15/2025ELMDElectromedB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/2/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/29/2025DRTSAlpha Tau MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/21/2025NYXHNyxoahStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.004/8/2025NYXHNyxoahHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.004/3/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.004/1/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/26/2025NYXHNyxoahHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $15.003/17/2025DRTSAlpha Tau MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$35.33M1.90N/AN/A$0.52 per share2.06DRTSAlpha Tau MedicalN/AN/AN/AN/A$1.21 per shareN/AELMDElectromed$61.44M2.73$0.48 per share41.36$5.10 per share3.92NYXHNyxoah$4.36M59.00N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$28.51M-$0.28N/AN/AN/A-49.47%-118.54%-42.31%8/12/2025 (Estimated)DRTSAlpha Tau Medical-$29.16M-$0.46N/AN/AN/AN/A-38.62%-29.89%8/13/2025 (Estimated)ELMDElectromed$5.15M$0.7926.68∞N/A11.34%15.71%13.37%N/ANYXHNyxoah-$46.77M-$2.13N/AN/AN/A-1,043.93%-51.68%-40.11%8/5/2025 (Estimated)Latest CTSO, NYXH, DRTS, and ELMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025DRTSAlpha Tau Medical-$0.14-$0.12+$0.02-$0.12$0.03 millionN/A5/14/2025Q1 2025CTSOCytosorbents-$0.08-$0.06+$0.02-$0.02$9.01 million$8.73 million5/14/2025Q1 2025NYXHNyxoah-$0.49-$0.63-$0.14-$0.63$1.64 million$1.12 million3/31/2025Q4 2024CTSOCytosorbents-$0.07-$0.03+$0.04-$0.14$10.09 million$9.20 million3/13/2025Q4 2024NYXHNyxoah-$0.46-$0.49-$0.03-$0.49$2.02 million$1.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/ADRTSAlpha Tau MedicalN/AN/AN/AN/AN/AELMDElectromedN/AN/AN/AN/AN/ANYXHNyxoahN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents1.061.971.58DRTSAlpha Tau Medical0.0810.99N/AELMDElectromedN/A5.104.74NYXHNyxoah0.215.284.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%DRTSAlpha Tau Medical2.65%ELMDElectromed40.82%NYXHNyxoahN/AInsider OwnershipCompanyInsider OwnershipCTSOCytosorbents6.60%DRTSAlpha Tau Medical39.50%ELMDElectromed14.00%NYXHNyxoah17.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22062.61 million51.07 millionOptionableDRTSAlpha Tau Medical8070.38 million42.30 millionNo DataELMDElectromed1608.39 million7.36 millionOptionableNYXHNyxoah11034.06 million28.23 millionNot OptionableCTSO, NYXH, DRTS, and ELMD HeadlinesRecent News About These CompaniesInvitation to attend the extraordinary shareholders' meeting of the Company to be held on July 2, 2025June 13 at 1:00 AM | globenewswire.comCantor Fitzgerald Predicts Nyxoah FY2026 EarningsJune 11 at 2:23 AM | americanbankingnews.comBrokers Set Expectations for Nyxoah FY2026 EarningsJune 10 at 8:56 AM | marketbeat.comNyxoah to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comKepler Capital Reaffirms Their Buy Rating on Nyxoah (NYXH)May 24, 2025 | theglobeandmail.comVestal Point Capital LP Invests $23.39 Million in Nyxoah S.A. (NASDAQ:NYXH)May 21, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHMay 18, 2025 | gurufocus.comNyxoah outlines U.S. Genio launch plan with 50-member team as FDA approval expected Q2 2025May 16, 2025 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHMay 16, 2025 | accessnewswire.comNyxoah S.A. (NASDAQ:NYXH) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comNyxoah SA (NYXH) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesMay 15, 2025 | finance.yahoo.comNyxoah SA (NYXH) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHMay 14, 2025 | accessnewswire.comNyxoah SA (NYXH) Reports Q1 Loss, Lags Revenue EstimatesMay 14, 2025 | zacks.comNyxoah Reports First Quarter Financial and Operating ResultsMay 14, 2025 | globenewswire.com1NYXH : Examining the Future: Nyxoah's Earnings OutlookMay 14, 2025 | benzinga.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nyxoah S.A. – NYXHMay 13, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHMay 12, 2025 | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHMay 12, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHMay 10, 2025 | accessnewswire.comPublication relating to transparency notificationsMay 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTSO, NYXH, DRTS, and ELMD Company DescriptionsCytosorbents NASDAQ:CTSO$1.07 -0.02 (-1.83%) As of 06/12/2025 04:00 PM EasternCytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Alpha Tau Medical NASDAQ:DRTS$3.07 0.00 (0.00%) As of 06/12/2025 03:58 PM EasternAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Electromed NYSE:ELMD$20.01 -0.04 (-0.20%) As of 06/12/2025 04:00 PM EasternElectromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.Nyxoah NASDAQ:NYXH$7.56 -0.19 (-2.45%) As of 06/12/2025 04:00 PM EasternNyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
